Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Multiple Myeloma × binimetinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 17 Lung Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Brain Neoplasms 6 Colorectal Neoplasms 4 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasms 2 Gastrointestinal Stromal Tumors 2 Breast Neoplasms 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Soft Tissue Neoplasms 1 Skin Neoplasms 1 Rectal Neoplasms 1 Peripheral Nervous System Neoplasms 1 Non-small Cell Carcinoma 1 Neurofibromatosis 1 1 Neurofibromatoses 1 Neurofibroma, Plexiform 1 Neurofibroma 1 Multiple Myeloma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1

Interventions

Dexamethasone 379 Lenalidomide 237 Cyclophosphamide 223 Bortezomib 212 Melphalan 176 Calcium Dobesilate 149 fludarabine phosphate 95 daratumumab 93 Peripheral Blood Stem Cell Transplantation 89 carfilzomib 80 Filgrastim 80 Thalidomide 77 Whole-Body Irradiation 74 pomalidomide 73 fludarabine 73 Mycophenolic Acid 69 Busulfan 63 Tacrolimus 59 Granulocyte Colony-Stimulating Factor 59 ixazomib 52 dexamethasone acetate 52 Cyclosporine 52 dexamethasone 21-phosphate 45 Antilymphocyte Serum 45 auricularum 41 Etoposide 35 Radiotherapy 34 Stem Cell Transplantation 33 isatuximab 30 Bendamustine Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02834364 2023-11-24

GMMG-BIRMA

University of Heidelberg Medical Center

Phase 2 Completed

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡